Additionally, there are dichotomous modulators such as DYRK1A, which depending on tumour type, can stimulate the Hh pathway by promoting the nuclear translocation of GLI1 or induce its degradation by acting negatively on the cytoskeleton [66]. The gene discussed is GLI1; the disease is neoplasm.